Loading...
Loading...
In a report published Wednesday, Jefferies analyst Raj Denhoy reiterated a Buy rating on
Medtronic PLCMDT, and raised the price target from $83.00 to $89.00.
In the report, Jefferies noted, "MDT posted a very good F3Q, highlighted by: strength in CRDM, where the US quadpole launch is yielding ICD share capture from STJ and Linq continues to be a star performer; CoreValve, where TAVR market growth remains robust; and improvement in Spine. The revenue growth outlook and cost synergy targets of the Covidien deal are intact. Reiterate Buy."
Medtronic closed on Tuesday at $78.07.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in